About this trial
This non-interventional study aims to develop spatial proteomics for analyzing small FFPE tumor samples in rhabdomyosarcoma. It will identify molecular signatures linked to tumor regions, subtypes, survival, and treatment resistance, using pre-existing samples and data.
Eligibility criteria
Qualifiers
Age between 0 and 25 years at the time of initial diagnosis
Diagnosis of rhabdomyosarcoma confirmed histologically
Care at the Oscar Lambret Center between January 2005 and November 2024
No objection to the re-use of data and biological samples collected as part of care for research activities.
Disqualifiers
Unavailability of biological sample in FFPE from biopsy and/or surgical specimen for diagnosis at Centre Oscar Lambret;
Patient under guardianship or trusteeship.
Trial design
Treatments tested in this trial
- None AHT
Treatment groups
Sponsors and collaborators
Lille University
Lead sponsor
Centre Oscar Lambret, Lille, France
Collaborator